Literature DB >> 35082372

Risankizumab improves PsA.

Sarah Onuora1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35082372     DOI： 10.1038/s41584-022-00751-1

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  2 in total

1.  Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.

Authors:  Lars Erik Kristensen; Mauro Keiserman; Kim Papp; Leslie McCasland; Douglas White; Wenjing Lu; Zailong Wang; Ahmed M Soliman; Ann Eldred; Lisa Barcomb; Frank Behrens
Journal:  Ann Rheum Dis       Date:  2021-12-15       Impact factor: 19.103

2.  Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.

Authors:  Andrew Östör; Filip Van den Bosch; Kim Papp; Cecilia Asnal; Ricardo Blanco; Jacob Aelion; Gabriela Alperovich; Wenjing Lu; Zailong Wang; Ahmed M Soliman; Ann Eldred; Lisa Barcomb; Alan Kivitz
Journal:  Ann Rheum Dis       Date:  2021-11-23       Impact factor: 19.103
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.